A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R

Ahn-Gook Pharmaceuticals Co.,Ltd158 enrolled

Overview

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

158

Conditions

Hypercholesterolemia

Interventions

AG2304TDRUG

AG2304T, QD, PO

AG2304RDRUG

AG2304R, QD, PO

Eligibility

Sex: ALLMin age: 19 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults aged 19-80 * Patients with primary hypercholesterolemia * Those who voluntarily written consent to participate in this clinical trial Exclusion Criteria: * The subject not meet the specified LDL-C level * Other exclusions applied

Locations (1)

AhnGook

Seoul, South Korea

Outcomes

Primary Outcomes

LDL-C level

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.